Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep demonstrates 69% ORR in pancreatic cancer
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5338)
•••
Comment by Noteableon Oct 19, 2023 4:51pm
150 Views
Post# 35691808

RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancer

RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancerThe Global pancreatic cancer market was valued at USD 2.05 billion in 2022 will expand to USD 7.40 billion by 2032. 

Globally, the pancreatic cancer market is increasing due to rising cancer prevalence, change in lifestyle, for example increase in the consumption of alcohol and smoking. 

The global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022
 
And with the potential use of pelareorep in combination with a checkpoint and CDK4/6 or PARP inhibitor,  in 2L HR+/HER2- advanced or metastatic breast cancer, in which optimal second-line therapy for hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer is yet to be established, ONCYs acquisition valuation still remains in the multi-Billions.

Nothing has changed for ONCY other than pelareorep will be used as second line treatment in HR+/HER2- (or HER2 low) advanced or metastatic breast cancer , when combined with a CPI, on the expected treatment relapes/failures/adverse effects with the ADC Enertu.

https://pubmed.ncbi.nlm.nih.gov/37026492/

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities